DV
Dividend Vision

PHVS — Pharvaris BV

Pharvaris BV (PHVS)

Total return is 21.2% over the past 5.5 years, 94.5 points behind SPY at 115.7%. Its deepest 1-year drawdown was 19.4%.

Pharvaris N.V. is a late-stage biopharmaceutical company developing therapies for rare diseases, specifically focusing on deucrictibant, a small molecule treatment for bradykinin-mediated angioedema conditions including hereditary angioedema and acquired angioedema, with the drug currently in phase 3 clinical trials in multiple formulations. The company does not currently distribute dividends. Pharvaris appeals to investors seeking exposure to late-stage biotech development with a focus on rare disease therapeutics, though the stock carries the inherent risks of clinical development and regulatory approval.

PHVS key facts

Asset type
Stock
Asset class
Equity
Inception date
02/05/2021
Last close
$35.14
Market cap
$2,344,464,896
Average volume
862899.0
Beta
-2.336
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.98